KPRX
Kiora Pharmaceuticals, Inc.NASDAQHealthcare$1.94-0.51%ClosedMarket Cap: $7.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.52
P/S
0.00
EV/EBITDA
0.04
DCF Value
$2.55
FCF Yield
-126.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.4%
ROA
-44.7%
ROIC
-40.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-3.9M | $-6.5M | $-1.59 | — |
| FY 2025 | $0.00 | -Infinity% | $-9.5M | $-10.8M | $-2.64 | — |
| Q3 2025 | $0.00 | -Infinity% | $-794.4K | $26.8K | $0.01 | — |
| Q2 2025 | $0.00 | NaN% | $-2.4M | $-2.2M | $-0.54 | — |
| Q1 2025 | $0.00 | NaN% | $-2.3M | $-2.2M | $-0.52 | — |
| Q4 2024 | $0.00 | NaN% | $-2.6M | $-4.2M | $-1.41 | — |
| FY 2024 | $16.0M | 100.0% | $4.5M | $3.6M | $0.87 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.4M | $-0.81 | — |
| Q2 2024 | $0.00 | NaN% | $-2.5M | $-2.2M | $-0.53 | — |
| Q1 2024 | $16.0M | 100.0% | $13.2M | $13.5M | $3.46 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.0M | $-2.3M | $-0.29 | — |
| FY 2023 | $0.00 | NaN% | $-12.6M | $-12.5M | $-24.25 | — |